Rezolute is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients suffering from debilitating metabolic diseases. Their primary focus is on hyperinsulinism-related hypoglycemia and diabetic retinal disease. The company's lead candidate, ersodetug, is an antibody therapy targeting insulin receptor signaling to reduce the clinical impact of excess insulin.